LIke ThisLIke ThisLIke This

Thomas Look, MD

Thomas Look, MD
Research Center:
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Medicine Research
Hematology/Oncology Research
Hospital Title:
Vice Chair for Research, Department of Pediatric Oncology
Academic Title:
Professor of Pediatrics
Research Focus Area:

Research Overview

The ultimate goal of the Look group's studies is to reveal mutant genes, thus providing candidate targets for the development of new therapies. To this end it is exploring:

  • Models of leukemogenesis,particularly the antiapoptotic transcriptional pathway downstream of E2A-HLF, a chimeric oncoprotein activated by chromosomal translocation in childhood leukemia.
  • Developmental pathways subverted in human leukemias and solid tumors. They are conducting a genome-wide mutagenesis screen in zebrafish to identify genes required for normal myeloid cell development in the hematopoietic system.
  • Pathways that lead to T-cell leukemia. They have shown that human T-cell leukemias can be divided into five major subtypes based on the expression of oncogenes that initiate malignant transformation in thymocytes and have overexpressed these oncogenes in zebrafish T-cell progenitors.

About Thomas Look

Thomas Look received his MD and completed an internship and residency in pediatrics at the University of Michigan. He subsequently completed his fellowship in pediatric oncology at St. Jude Childrens Research Hospital in Memphis.He was named Second Annual Lecturer in Leukemia at The Hospital for Sick Children, Toronto, Canada, 2000; Second Annual Giulio J. D'Angio Lecturer, University of Pennsylvania Cancer Center, 1999; and received an Award for Excellence in Pediatric Research, American Academy of Pediatrics, 1995.

LIke ThisLIke ThisLIke This


Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is one of the top research centers in the world for pediatric cancers and blood diseases. It brings together laboratory scientists and clinical researchers from Dana-Farber Cancer Institute and Boston Children’s Hospital in a single program. We investigate pediatric cancers and non-malignant blood disorders from every angle—from examining cells under the microscope to tracking the effectiveness of current drug regimens using the most advanced molecular methods—so that we can create better treatments for children seen here and around the world.

Learn more